2022-01-262022-01-262009-11Eker, S. S. vd. (2009). "The potential relationship between QTc interval prolongation and ziprasidone treatment: Three cases". Journal of Psychopharmacology, 23(8), 993-996.0269-8811https://doi.org/10.1177/0269881108093843https://journals.sagepub.com/doi/10.1177/0269881108093843http://hdl.handle.net/11452/24297QTc interval prolongation may appear as a consequence of both typical and atypical antipsychotic treatments. Ziprasidone, which is effective in treating schizophrenia, is associated with QTc prolongation. Although the prolongation of QTc with ziprasidone treatment is often pronounced, there is a scarce number of cases reported about the relationship between ziprasidone and QTc prolongation. Of the three cases presented in this case series, two cases showed values exceeding 0.50 s with ziprasidone treatment.eninfo:eu-repo/semantics/closedAccessAntipsychoticQTc prolongationZiprasidoneTorsade-de-pointesSchizoaffective disorderAntipsychotic-drugsAcute exacerbationDouble-blind160 mg/daySchizophreniaSafetyHaloperidolManagementNeurosciences & neurologyPharmacology & pharmacyPsychiatryAdultAntipsychotic agentsElectrocardiographyFemaleHumansMaleMiddle agedPiperazinesThiazolesArticle0002714960000182-s2.0-7044941996999399623818635710Clinical neurologyNeurosciencesPharmacology & pharmacyPsychiatryNeuroleptic Agent; Prolongation; ZiprasidoneAmisulprideBiperidenBornaprineGlimepirideHaloperidolLithiumMetforminQuetiapineValproic acidVenlafaxineZiprasidoneZuclopenthixol decanoateAdultArticleCase reportDiabetes mellitusDiagnostic and statistical manual of mental disordersDisease exacerbationDrug blood levelDrug dose increaseDrug dose reductionDrug efficacyDrug responseDrug substitutionDrug withdrawalFemaleHumanMalePriority journalPsychosisQT prolongationSchizophrenia